CAC
RLMD icon

Cowen and Company’s Relmada Therapeutics RLMD Stock Holding History

Cowen and Company’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,500
Closed -$65K – 689
2021
Q2 		$65K Buy
+13,500
New +$469K ﹤0.01% 379

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen and Company's RLMD Position: Q1 2023 in Review

Cowen and Company sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 64,011 shares — an estimated $223K sold.

Cowen and Company first reported a position in RLMD in Q1 2021 and held it in 8 quarters. The position peaked at $31.4M in Q1 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Cowen and Company reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 64,011 Relmada Therapeutics shares in Q1 2023, an estimated $223K.
  • Cowen and Company first reported a position in Relmada Therapeutics in Q1 2021 and held it in 8 quarters.
  • Cowen and Company's Relmada Therapeutics position peaked at $31.4M in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.